Febuxostat, effectve treatment for chronic gout and hyperuricemia

Published: 2004-11-04 06:57:00

Updated: 2004-11-04 06:57:00

SK Chemicals and SK Pharm said that TAP Pharmaceutical Products Inc., a joint venture between Abbott and Takeda Pharm, announced its October 19 data showing its investigational medication, febuxostat (codename: TMX-67), lowered uric acid levels among patients with chronic gout in a Phase II clinical trial. The data were presented at the 68th Annual Scientific Meeting at the American College of ...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.